Patent Application
20150072003
The present invention relates to a fixed dose combination formulation, a process for the preparation thereof and its use in the treatment of diseases.
Active pharmaceutical ingredients showing an ester, amide or thioester functionality, such as S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate, are often sensitive to moisture and frequently show chemical incompatibility with a wide range of commonly used pharmaceutical excipients, thus typical composition approaches such as lipid based drug delivery systems can not be considered. Incorporating the drug substance into a hygroscopic polymer matrix can be critical due to chemical as well as physical stability. The sorption of moisture by excipients in solid dosage forms can lead to considerable stability problems when the contained active pharmaceutical is instable in water due to the presence of a hydrolysis sensitive functional group. Though theoretically hygroscopic polymers are capable to bind moisture in the composition, thus protecting the active pharmaceutical ingredient from hydrolysis, a fairly high amount of polymer is needed to achieve this, what usually leads to capping or cracking of the immediate-release tablet composition. Thus, it is usually imperative to prevent moisture sorption during storage by both, a suitable composition and primary packaging.
The manufacturing of the composition according to the present invention shows surprisingly better flowability than past compositions comprising a hydrophobic, water instable compound with a waxy consistency. For instance, the composition according to the present invention does not demonstrate extreme funnel flow.
In a first aspect the present invention provides a composition comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate (a hydrophobic, water instable compound with a waxy consistency), a super-disintegrant and atorvastatin.
In a second aspect the present invention provides a composition comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate (a hydrophobic, water instable compound with a waxy consistency), a super-disintegrant, atorvastatin and at least two diluents with a bulk density lower than 800 g/L.
The invention also provides a method for treating or preventing a cardiovascular disorder in a mammal by administering to a mammal in need of such treatment a therapeutically effective amount of the composition provided by the invention.
The invention further provides a composition for treating or preventing a cardiovascular disorder. A composition according to the present invention for the use in the treatment or prevention of cardiovascular disorder is also part of the invention.
The hygroscopic matrix based composition is useful to chemically stabilize a hydrophobic and hydrolysis sensitive compound with a waxy consistency, such as S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and to stabilize the physical properties of a tablet comprising said composition.
Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:
The term “bulk density” refers to a density measurement of a loose, uncompacted substance, wherein the volume of the substance includes the air trapped between particles. The bulk density is measured in a graduated cylinder according to the European Pharmacopeia.
The term “diluent” refers to an excipient which fills out the size of a tablet or capsule, making it practical to produce and convenient for the consumer to use. Suitable diluents include e.g. pharmaceutically acceptable fillers, such as microcrystalline cellulose (e.g. Avicel®), crospovidone micronized, cellulose powder, lactose spray-dried, lactose anhydrous, lactose monohydrate, dibasic calcium phosphate, sugars, sugar alcohols, corn starch, starch, pregelatinized starch, colloidal silicon dioxide, polysaccharides, and mixtures thereof.
The term “hydrophobic” means insoluble in water, not readily absorbing moisture, or being adversely affected by water; either incompatible with water or having little affinity for it. In other words the hydrophobic drug or compound would not spontaneously disperse in water. Specifically hydrophobic means log P>3. The log P is measured or in the absence of experimental data calculated as c log P according to the model developed by Moriguchi (S. Moriguchi, S. Hirono, I. Nakagome, H. Hirano, (1994). “Comparison of reliability of log P values for drugs calculated by several methods” Chem Pharm Bull 1994, 42: 976-978).
The term “hygroscopic polymeric excipient(s)” means polymeric excipient(s) which take(s) up moisture for example by absorption or adsorption even at relative humidity as low as 50%, at room temperature (e.g. about 25° C.). The moisture uptake is measured e.g by dynamic vapor sorption at room temperature. As an example the hygroscopicity can be measured in accordance with the method disclosed in the European Pharmacopoeia—6th Edition (2008), Chapter 5.11. The dynamic vapor sorption technique measures the change in mass which is produced by varying the vapor concentration surrounding the product. Suitable “hygroscopic polymeric excipients” are hydroxypropyl methylcellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxyethylmethyl cellulose, carboxypolymethylene, methylcellulose, ethylcellulose, hydroxyethyl cellulose, celluloseacetate, polyvinylpyrrolidone crosslinked polyvinylpyrrolidone, micronized crosslinked polyvinylpyrrolidone, carboxymethylcellulose sodium, carboxymethylcellulose calcium, crosslinked carboxymethylcellulose, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powder, carboxymethyl starch, starch, pregelatinized starch or mixture thereof. In particular “hygroscopic polymeric excipients” refer to hydroxypropyl methylcellulose, carboxymethylcellulose sodium, microcrystalline cellulose and micronized crosslinked polyvinylpyrrolidone. Examples of “water insoluble hygroscopic polymers” at room temperature (e.g. about 25° C.) include low-substituted hydroxypropyl cellulose, carboxypolymethylene, ethylcellulose, celluloseacetate, crosslinked polyvinylpyrrolidone, micronized crosslinked polyvinylpyrrolidone, carboxymethylcellulose calcium, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powder, and starch.
The term “Super-disintegrant” refers to disintegrants that very rapidly expand upon contact with water. Generally speaking, superdisintegrants are disintegration agents which can be used in a fractional amount of normal disintegrants to obtain the same effect. Examples of superdisintegrants include cross-linked carboxymethyl cellulose sodium (a.k.a. croscarmellose sodium), sodium starch glycolate, and cross-linked polyvinyl pyrollidone (a.k.a. crospovidone). Croscarmellose sodium is commercially available from FMC Corp. under the trade name Ac-Di-Sol® and from Avebe Corp. under the trade name Primellose®. Sodium starch glycolate is commercially available from Pen west Pharmaceuticals Co. under the tradename Explotab® and from Avebe Corp. under the tradename Crospovidone is commercially available from BASF Corp. under the tradename Kollidon® CL and from International Specialty Chemicals Corp. under the tradename Polyplasdone®. Croscarmellose is also commercially available from Mingtai Chemical Co. Ltd under the tradename DISOLCEL® and from J. Rettenmaier & Söhne GmbH+Co (JRS) under the tradename Vivasol®. The most preferred superdisintegrants are croscarmellose sodium and crospovidone.
The term “water instable” means the presence of a hydrolysis sensitive functional group like an ester, amide or thioester.
The term “waxy consistency” means that the glass transition temperature (Tg) is lower than 25° C.
The term “pharmaceutical acceptable metal salt” refers to sodium, potassium, lithium, calcium, magnesium, aluminum, iron, or zinc salts.
The term “PVA” and “PVOH” are interchangeable and refer to a polyvinyl alcohol which in particular are polyvinyl resins having hydroxyl groups and is obtained through saponification of polyvinyl acetate (polymerized vinyl acetate). More particularly the polyvinyl alcohol are obtained from Nippon-Gohsei (Gohsenol).
S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate is also known as thioisobutyric acid S-(2-{[1-(2-ethyl-butyl)-cyclohexanecarbonyl]-amino}-phenyl) ester, dalcetrapib or a compound of formula I
Atorvastatin refers to atorvastatin pharmaceutically acceptable salts and/or hydrates also known as [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, (2R-trans)5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2Hpyran-2-yl)ethyl-1H-pyrrole-3-carboxamide, atorvastatin acid or a compound of formula (II′)
pharmaceutical acceptable salts and/or hydrates. Atorvastatin refers in particular to [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid pharmaceutically acceptable salts and/or hydrate. The pharmaceutically salt is selected from monosodium salt, monopotassium salt, hemicalclium salt, N-methylglucamine salt, hemimagnesium salt or hemizinc salt, in particular hemicalclium salt or hemimagnesium salt, more particularly hemicalclium salt. More particularly atorvastatin refers to hemicalcium salt of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid also known [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt or [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1). Its chemical structure may be represented by formula (II):
Even more particularly atorvastatin refers to [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate, most particularly in crystalline form I as disclosed in WO9703959. Form I is characterized by an X-ray powder diffraction pattern having peaks at about 9.2, 9.5, 10.3, 10.6, 11.9, 12.2, 17.2, 19.5, 21.6, 22.0, 22.7, 23.3, 23.7, 24.4, 28.9 and 29.2±0.2°, particularly by an XRPD peaks observed at an angle of diffraction 2Theta of 11.9, 17.1 and 21.6)(±0.2°.
Atorvastatin calcium is currently been sold as Lipitor®. Lipitor Atorvastatin has been described in EP1061073 B1, EPO409281 B1, EP0848705B1, EP 1148049 B1, EP0247633B1 and WO9416693.
Atorvastatin is a synthetic reversible inhibitor of the microsomal enzyme HMG-CoA reductase. Atorvastatin is usually administered orally as the calcium salt of the active hydroxyl acid in a dosage range of 10-80 mg/day. Atorvastatin acid is converted to its lactone in vivo in humans, and these two forms appear to have approximately the same AUC (Area Under the Curve).
Lipitor® tablets for oral administration comprise 10 mg, 20 mg, 40 mg or 80 mg atorvastatin and the following excipients: calcium carbonate, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, simethicone emulsion, talc, and titanium dioxide. In addition Lipitor® may comprise candelilla wax.
Atorvastatin is unstable, as it is susceptible to heat, moisture, low pH environment and light. In acidic environment, atorvastatin will degrade to lactone. Furthermore, atorvastatin will decompose rapidly when exposed to UV or fluorescent lights. Atorvastatin may be destabilized by contact with molecular moieties of other components such excipients used in the core layer, dal layer or atv layer, or/and dalcetrapib. Therefore a stabilizing means may be required for effective pharmaceutical dosages.
In another embodiment of the present invention, at least one pharmaceutically acceptable stabilizing additive is present. In particular, the pharmaceutically acceptable stabilizing additive would be in close vicinity to atorvastatin. More particularly, the pharmaceutically acceptable stabilizing additive is present in the active coating comprising atorvastatin or in the atv layer. In particular the pharmaceutically acceptable stabilizing additive is selected from alkaline earth metal salts such as, calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium carbonate, magnesium hydroxide, magnesium silicate, magnesium aluminate or aluminum magnesium hydroxide, or a mixture thereof. More particularly the pharmaceutically acceptable stabilizing additive is calcium carbonate.
In another embodiment of the invention, polyethylene glycol is not present in the active coating.
According to the present invention, the composition needs to maintain a good dissolution rate of atorvastatin and dalcetrapib, in particular similar to the mono-therapy compositions of atorvastatin and dalcetrapib. In particular, the composition according to the present invention produces similar exposures of dalcetrapib and atorvastatin to the mono-therapy reference tablets.
More particularly, according to a more particular embodiment of the present invention, the composition shows similar impurities profile to the mono-therapy reference tablets, atorvastatin and dalcetrapib.
Calcium carbonate has some incompatibilities with dalcetrapib and/or with some of the impurities of dalcetrapib. It increases the formation of iso-butyric acid which in turn increases the atorvastatin lactone formation.
When calcium carbonate is not present in the active coating, the dissolution rate of atorvastatin increases, which in turn increases the dalcetrapib dissolution.
Unless otherwise stated all percentages are given in weight percent of the total weight of the composition.
S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate has been shown to be an inhibitor of CETP activity in humans (de Grooth et al., Circulation, 105, 2159-2165 (2002)) and rabbits (Shinkai et al., J. Med. Chem., 43, 3566-3572 (2000); Kobayashi et al., Atherosclerosis, 162, 131-135 (2002); and Okamoto et al., Nature, 406 (13), 203-207 (2000)). S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate has been shown to increase plasma HDL cholesterol in humans (de Grooth et al., supra) and in rabbits (Shinkai et al., supra; Kobayashi et al., supra; Okamoto et al., supra). Moreover, S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate has been shown to decrease LDL cholesterol in humans (de Grooth et al., supra) and rabbits (Okamoto et al., supra). Additionally, S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate inhibits the progression of atherosclerosis in rabbits (Okamoto et al., supra). S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate, as well as methods of making and using the compound, are described in EP patent EP1020439, Shinkai et al., J. Med. Chem. 43:3566-3572 (2000) or WO 2007/051714, WO 2008/074677 or WO2011/000793.
In a particular embodiment S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate is a solid in crystalline or amorphous form, more particularly in crystalline form. In a particular embodiment S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate is in crystalline form A.
Form A is characterized by an X-ray powder diffraction pattern having peaks at about 7.9°, 8.5°, 11.7°, 12.7°, 17.1°, 18.0°, 18.5°, 20.2°, 22.1°, 24.7°±0.2°, particularly by an XRPD peaks observed at an angle of diffraction 2Theta of 7.9°, 11.7°, 17.1°, 18.5° (±0.2°).
The composition can be used to treat or prevent a cardiovascular disorder, including, but not limited to, atherosclerosis, peripheral vascular disease, dyslipidemia (e.g., hyperlipidimia), hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, cardiovascular disease, coronary heart disease, coronary artery disease, acute coronary syndrome, hyperlipidoproteinemia, vascular complications of diabetes, obesity or endotoxemia in a mammal, especially a human (i.e., a male or female human). The composition can be used to reduce cardiovascular morbidity and mortality.
Accordingly, the invention provides a method for the treatment or prophylaxis of a cardiovascular disorder in a mammal, which method comprises administering to a mammal (particularly a mammal in need thereof) a therapeutically effective amount of the composition. The mammal particularly is a human (i.e., a male or female human). The human can be of any race (e.g., Caucasian or Oriental). The cardiovascular disorder particularly is selected from the group consisting of atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia in a mammal. More particularly, the cardiovascular disorder is selected from the group consisting of cardiovascular disease, coronary heart disease, coronary artery disease, acute coronary syndrome, hypoalphalipoproteinemia, hyperbetalipoproteinemia, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, hypertriglyceridemia, hyperlipidoproteinemia, peripheral vascular disease, angina, ischemia, and myocardial infarction.
In particular embodiment of the invention, the composition comprises: a) a core comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and b) an active coating comprising atorvastatin or the composition comprises: a) one layer comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate (herein referred as dal layer) and b) another layer comprising atorvastatin (herein referred as atv layer). In particular, the active coating comprising atorvastatin would not be in contact with S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate.
In a particular embodiment of the invention, the composition is a fixed dose tablet, particularly in the form of a bilayer tablet or in an active coating tablet.
In certain embodiments of the present invention, the composition comprises: 10% to 69% by weight of the total weight of the core or dal layer, particularly 40% to 60% by weight of the total weight of the core or dal layer, more particularly 48% to 55% by weight of the total weight of the core or dal layer of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate.
In certain embodiments of the present invention, the composition comprises: 1% to 10% by weight of the total weight of the core or dal layer, particularly 5% to 10% by weight of the total weight of the core or dal layer, more particularly 4% to 8% by weight of the total weight of the core or dal layer of a super-disintegrant.
In certain embodiments of the present invention, the composition comprises 30% to 70% by weight of the total weight of the core or dal layer, particularly 30% to 60% by weight of the total weight of the core or dal layer, more particularly 40% to 50% by weight of the total weight of the core or dal layer of at least two diluents with a bulk density lower than 800 g/L.
In a particular embodiment, the present invention provides a composition comprising:
In certain embodiments of the present invention as defined herein, the super-disintegrant is a hygroscopic polymeric excipient. In particular the hygroscopic polymeric excipient as superdisintegrant is croscarmellose sodium.
In a particular embodiment, the present invention provides a composition comprising:
In another embodiment, the present invention provides a composition comprising:
In certain embodiments of the present invention as defined herein, the composition further comprises at least one additional hygroscopic polymeric excipient, in particular in the core or dal layer.
In certain embodiments of the present invention as defined herein, the composition further comprises at least two hygroscopic polymeric excipients, in particular in the core or dal layer.
In certain embodiments of the present invention as defined herein, the composition further comprises at least three hygroscopic polymeric excipients of which two are diluents with a bulk density lower than 800 g/L, in particular in the core or dal layer.
In certain embodiments of the present invention as defined herein, the composition comprises 10% to 69% by weight of the total weight of the core or dal layer of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate.
In certain embodiments of the present invention, the composition comprises: 10% to 69% by weight of the total weight of the core or dal layer, particularly 40% to 60% by weight of the total weight of the core or dal layer, more particularly 48% to 55% by weight of the total weight of the core or dal layer of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate.
In certain embodiments of the present invention as defined herein, the composition comprises 1% to 10% by weight of the total weight of the core or dal layer, particularly 5% to 10% by weight of the total weight of the core or dal layer, more particularly 5% to 8% by weight of the total weight of the core or dal layer of croscarmellose sodium. More particularly, in a certain embodiment, the composition comprises 5% to 7% by weight of the total weight of the core or dal layer of croscarmellose sodium.
In certain embodiments of the present invention as defined herein, the composition comprises at least 30% by weight of the total weight of the core or dal layer of the hygroscopic polymeric excipients, in particular 44% to 50% by weight of the total weight of the core or dal layer, more particularly 46% to 48% by weight of the total weight of the core or dal layer, wherein the hygroscopic polymeric excipients are hydroxypropylmethyl cellulose, croscarmellose sodium, microcrystalline cellulose and micronized crosslinked polyvinylpyrrolidone.
In certain embodiments of the present invention as defined herein, the composition comprises at least 30% by weight of the total weight of the core or dal layer of the hygroscopic polymeric excipients, particularly 34% to 44% by weight of the total weight of the core or dal layer, more particularly 40% to 44% by weight of the total weight of the core or dal layer.
In certain embodiments of the present invention as defined herein, the composition comprises at least 30% by weight of the total weight of the core or dal layer of the additional hygroscopic polymeric excipients, particularly 34% to 44% by weight of the total weight of the core or dal layer, more particularly 40% to 44% by weight of the total weight of the core or dal layer.
In a particular embodiment, the present invention provides a composition comprising:
In certain embodiments of the present invention as defined herein, the composition comprises:
In certain embodiments of the present invention as defined herein, wherein the hygroscopic polymeric excipients are selected from hydroxypropylmethyl cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxyethylmethyl cellulose, carboxypolymethylene, methylcellulose, ethylcellulose, hydroxyethyl cellulose, celluloseacetate, polyvinylpyrrolidone, crosslinked polyvinylpyrrolidone, micronized crosslinked polyvinylpyrrolidone, carboxymethylcellulose calcium, crosslinked carboxymethylcellulose, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powder, carboxymethyl starch, starch and pregelatinized starch.
In certain embodiments of the present invention as defined herein, wherein the hygroscopic polymeric excipients are hydroxypropylmethyl cellulose, microcrystalline cellulose and micronized crosslinked polyvinylpyrrolidone.
In certain embodiments of the present invention as defined herein, the two diluents are hygroscopic polymeric excipients. In particular the hygroscopic polymeric excipients as diluents are ethylcellulose, micronized crosslinked polyvinylpyrrolidone, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powder, starch, pregelatinized starch.
In certain embodiments of the present invention as defined herein, at least two hygroscopic polymeric excipients are present.
In certain embodiments of the present invention as defined herein, the super-disintegrant and at least one of the diluents, or at least two diluents are hygroscopic polymeric excipients. More particularly, at least the super-disintegrant and one of the diluents are hygroscopic polymeric excipients.
In certain embodiments of the present invention as defined herein, the super-disintegrant and the two diluents are hygroscopic polymeric excipients.
In certain embodiments of the present invention as defined herein, there is at least 30% by weight of the total weight of the core or dal layer of hygroscopic polymeric excipients, particularly 44% to 50% by weight of the total weight of the core or dal layer.
In certain embodiments of the present invention, the super-disintegrant is croscarmellose sodium. In particular, the present invention comprises up to 6% by weight of the total weight of the core or dal layer of croscarmellose sodium.
The invention provides a physically stable composition comprising a) at least S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate, a hydrophobic and water instable cholesteryl ester transfer protein (CETP) inhibitor embedded in a chemically protective hygroscopic polymer matrix tablet consisting of at least one hygroscopic polymer e.g. hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), low-substituted hydroxypropyl cellulose (L-HPC), hydroxyethylmethyl cellulose (HEMC), carboxypolymethylene (Carbomer), methylcellulose (MC), ethylcellulose (EC), hydroxyethyl cellulose (HEC), celluloseacetate, polyvinylpyrrolidone (PVP), crosslinked polyvinylpyrrolidone (Crospovidone), micronized crosslinked polyvinylpyrrolidone (crospovidone micronized), carboxymethylcellulose sodium (croscarmellose sodium, CMC Na), carboxymethylcellulose calcium (croscarmellose calcium, CMC Ca), crosslinked carboxymethylcellulose (Crosslinked CMC), microcrystalline cellulose (MCC), silicified microcrystalline cellulose (silicified MCC), cellulose powder, carboxymethyl starch (sodium starch glycolate), starch (maize starch, potato starch, rize starch, wheat starch, tapioca starch), pregelatinized starch or a combination thereof in an amount of particularly 40% by weight or more of the total weight of the core or dal layer and b) atorvastatin.
The invention provides a physically stable composition comprising a) a core or dal layer comprising at least S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate, a hydrophobic and water instable cholesteryl ester transfer protein (CETP) inhibitor embedded in a chemically protective hygroscopic polymer matrix tablet consisting of at least one hygroscopic polymer e.g. hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), low-substituted hydroxypropyl cellulose (L-HPC), hydroxyethylmethyl cellulose (HEMC), carboxypolymethylene (Carbomer), methylcellulose (MC), ethylcellulose (EC), hydroxyethyl cellulose (HEC), celluloseacetate, polyvinylpyrrolidone (PVP), crosslinked polyvinylpyrrolidone (Crospovidone), micronized crosslinked polyvinylpyrrolidone (crospovidone micronized), carboxymethylcellulose sodium (croscarmellose sodium, CMC Na), carboxymethylcellulose calcium (croscarmellose calcium, CMC Ca), crosslinked carboxymethylcellulose (Crosslinked CMC), microcrystalline cellulose (MCC), silicified microcrystalline cellulose (silicified MCC), cellulose powder, carboxymethyl starch (sodium starch glycolate), starch (maize starch, potato starch, rize starch, wheat starch, tapioca starch), pregelatinized starch or a combination thereof in an amount of particularly 40% by weight or more of the total weight of the core or dal layer; and b) a second or out layer comprising atorvastatin.
In particular, the present invention provides a physically stable composition comprising:
The invention provides a physically stable composition comprising a) at least S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate embedded in a chemically protective hygroscopic polymer matrix tablet consisting of hydroxypropylmethyl cellulose, carboxymethylcellulose sodium, microcrystalline cellulose and micronized crosslinked polyvinylpyrrolidone in an amount of particularly 40% by weight or more of the total weight of the core or dal layer and b) atorvastatin.
Usually bringing a moisture sensitive active pharmaceutical ingredient in contact with a high amount of hygroscopic polymers such as HPMC, HPC, PVP, Crospovidone, CMC, crosslinked CMC and MC is considered critical to physical stability.
Surprisingly it was found that in case of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate, a hydrophobic hydrolysis sensitive CETP inhibitor, a converse effect could be observed. It was possible to stabilize both, the active pharmaceutical ingredient and the immediate release tablet by embedding the active in a hygroscopic polymeric matrix comprising of:
Furthermore, it was surprisingly found that increasing the amount of hydroscopic polymers from its usual range of 10 to 20% by weight to more than 30% by weight of the total weight of the core or dal layer in the presence of hydrophobic compound did not lead to capping or cracking of the immediate-release tablet composition as would have been expected. Therefore the hydrophobic compound prevents the formation of cracks of the immediate release tablet when more than 30% by weight of the total weight of the core or dal layer of the tablet consists of hygroscopic polymeric excipients.
In another embodiment, the present invention provides a composition comprising:
In another embodiment, the present invention provides a composition comprising:
In another embodiment, the present invention provides a composition comprising:
In another embodiment, the present invention provides a composition comprising:
In another embodiment, the present invention provides a composition comprising:
In another embodiment, the present invention provides a composition comprising:
In another embodiment, the present invention provides a composition comprising:
In another embodiment, the present invention provides a composition comprising:
In another embodiment, the present invention provides a composition comprising:
In another embodiment the present invention provides a composition comprising:
In another embodiment the present invention provides a composition comprising:
In certain embodiment of the present invention, the active coating comprises:
In certain embodiment of the present invention, the active coating comprises:
In certain embodiment of the present invention, the active coating comprises:
In certain embodiment of the present invention, the active coating comprises:
In certain embodiment of the invention, the composition comprises
In another embodiment according to the present invention, the active coating comprising atorvastatin comprises:
In another embodiment according to the present invention, the atv layer comprising atorvastatin comprises:
In certain embodiment of the present invention, the atv layer comprises:
In a particular embodiment, the composition herein is film coated, in particular with a polymer coating, such as HPMC and HPC or polyvinyl alcohol-polyethylene glycol (Kollicoat® IR) or a polyvinyl alcohol based coat (PVA-based coat), particularly with 30 mg or less PVA-based coat, more particularly with 20 mg PVA-based coat.
In a particular embodiment, the composition herein is film coated with vinylpyrrolidone-vinyl acetatecopolymer (PVP VA 64 also known as Kollidon® VA 64), Triethylcitrate, Talcum and Titan dioxide.
Alternatively to the film forming polymer, the plasticizer, the filler and colours additives a ready to use mixture like Opadry II clear can be used.
In certain embodiment of the present invention, the core comprising dalcetrapib is separated from the active coating comprising atorvastatin by a separation layer. In particular, the separation layer comprises polyvinyl alcohol, triacetin and talcum. In another embodiment the separation layer comprises vinylpyrrolidone-vinyl acetatecopolymer (PVP VA 64 also known as Kollidon® VA 64) Triacetin and Talcum.
In certain embodiment of the present invention, the composition comprises a seal coat or a film coat as shown in
In certain embodiments of the present invention, the composition is a pharmaceutical composition.
The pharmaceutical composition can be, for example, in the form of a pill, capsule or tablet, each containing a predetermined amount of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and atorvastatin and in particular coated for ease of swallowing, in the form of a powder or granules. In particular, the pharmaceutical composition is in the form of a tablet comprising S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate, atorvastatin and the components of the tablet utilized and described therein. For oral administration, fine powders or granules may contain diluting, dispersing and/or surface active agents and may be present, for example, in capsules or sachets in the dry state, or in tablets wherein binders and lubricants may be included. Components such as sweeteners, flavoring agents, preservatives, suspending agents, thickening agents, and/or emulsifying agents also may be present in the pharmaceutical composition.
In certain embodiments of the present invention, the composition comprises 100 mg to 600 mg of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate. In particular, the composition comprises 150 mg to 450 mg of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate. More particularly, the composition comprises 250 mg to 350 mg of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate. Most particularly, the composition comprises 250 mg to 350 mg of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate.
In certain embodiments of the present invention, the composition comprises 300 mg of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and 5 mg, 10 mg, 20 mg or 40 mg of atorvastatin.
In another embodiment of the present invention, the composition comprises for pediatric use 25 mg to 300 mg of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate. In particular the pediatric composition comprises 75 mg to 150 mg of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate.
In another embodiment of the present invention, the composition comprises for pediatric use 150 mg of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and 5 mg, 10 mg or 20 mg of atorvastatin.
The CETP inhibitor can be administered to the mammal at any suitable dosage (e.g., to achieve a therapeutically effective amount). For example, a suitable dose of a therapeutically effective amount of Compound I for administration to a patient will be between approximately 100 mg to about 1800 mg per day. A desirable dose is particularly about 300 mg to about 900 mg per day. A preferred dose is about 600 mg per day.
In another embodiment the invention provides a kit comprising a composition comprising a therapeutically effective amount of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and atorvastatin and at least 30% by weight of hygroscopic polymeric excipients by composition weight, prescribing information also known as “leaflet”, a blister package or bottle (HDPE or glass) and a container. The prescribing information particularly includes the advice to a patient regarding the administration of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate with food, especially to improve the bioavailability of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate. In more particular, the prescribing information includes the advice to a patient regarding the administration of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and atorvastatin with food, especially to improve the bioavailability of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate.
In another embodiment the invention provides a kit comprising a composition as described herein, prescribing information also known as “leaflet”, a blister package or bottle (HDPE or glass) and a container. The prescribing information particularly includes the advice to a patient regarding the administration of the S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate with food, especially to improve the bioavailability of the S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate. More particularly the prescribing information includes the advice to a patient regarding the administration of the S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and atorvastatin with food, especially to improve the bioavailability of the S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate.
In another embodiment, the invention provides a kit comprising a composition comprising a therapeutically effective amount of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and atorvastatin, and at least 30% by weight of hygroscopic polymeric excipients by composition weight, prescribing information, a blister package or bottle and a container. In particular embodiment the invention provides the kit as described herein, wherein the prescribing information includes the advice to a patient regarding the administration of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate with food.
In another embodiment, the invention provides a tablet comprising the composition as herein described.
In another embodiment, the invention provides a composition as herein described for preparing a medicament for the treatment or prevention of cardiovascular disorder, in particular wherein the S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate is administered at a daily dose of 100 mg to 1800 mg, particularly 300 mg to 900 mg, more particularly 600 mg, more particularly wherein S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate is administered with food.
In another embodiment, the invention provides a process for the preparation of the composition comprising the following steps:
In another embodiment, the invention provides a process for the preparation of the composition comprising the following steps:
In another embodiment the present invention provides a process for the preparation of the composition as described herein, which comprises the following steps:
In another embodiment the present invention provides a process for the preparation of the composition as described herein, which comprises the following steps:
In another embodiment the present invention provides a process for the preparation of the composition as described herein, which comprises the following steps:
In another embodiment, the invention provides a process for the preparation the dal layer comprising the following steps:
In another embodiment, the invention provides a process for the preparation the atv layer comprising the following steps:
In another embodiment, the invention provides a process for the preparation the composition according to the present invention comprising the following steps:
Herein, the API 1 refers to the active substance S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate which is a hydrophobic, water instable compound with a waxy consistency. The API 2 refers in examples 2 to 70 to the active substance [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate. In the examples 1 to 70 the API 1 refers to S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate of formula (I′) in crystalline form.
The composition of the present invention may be prepared according to any known process which results in keeping the API 1 substantially in crystalline form (the amount of the hydrophobic, API 1 in amorphous does not exceed 10% by weight). Furthermore, the composition of the present invention may be prepared according to any known process which results in keeping the API 1 substantially in crystalline form (the amount of the hydrophobic, water instable compound with a waxy consistency substantially in amorphous does not exceed 10% by weight).
The composition of the present invention may be prepared according to any known process which results in keeping the API 2 substantially in crystalline form (the amount of API 2 in amorphous does not exceed 10% by weight). Furthermore, the composition of the present invention may be prepared according to any known process which results in keeping the API 2 substantially in crystalline form (the amount of API 2 in amorphous does not exceed 10% by weight).
The process for preparing the core or dal layer composition according to the invention may comprise the following steps:
The process for preparing active coating composition according to the invention may comprise the following steps:
The process for preparing by layer tablet composition according to the invention may comprise the following steps:
Other features and embodiments of the invention will become apparent from the following examples which are given for illustration of the invention rather than for limiting its intended scope.
Examples 1 to 46 and placebo example A were prepared according to the above mentioned general processes, wherein the API 1 for example A has been replaced with mannitol. Examples 47 to 70 are prepared according to the above mentioned general processes. Examples 22 to 30, 36 to 46 and 62 to 70 were all film coated with 20 mg PVA-based coat (e.g. Opadry® e.g. Opadry II white 85F18422).
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
1In suspension (solvent free)
Two tablets produced according to example 1 and example A were sliced and their X-ray pictures were collected. Both figures represent an overlayed of all X-ray slices that were generated during the measurement to reconstruct the 3D tablet. While
XRPD patterns of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate crystalline form A were recorded at ambient conditions in transmission geometry with a STOE STADI P diffractometer (Cu K alpha radiation source, primary monochromator, position sensitive detector, angular range 3° to 42° 2Theta, approximately 60 minutes total measurement time). The samples were prepared and analyzed without further processing (e.g. grinding or sieving) of the substance.
| Number | Date | Country | Kind |
|---|---|---|---|
| 12166211.8 | Apr 2012 | EP | regional |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/EP2013/058685 | Apr 2013 | US |
| Child | 14526030 | US |
